Epigenetic therapy in hematological cancers

TY - JOUR

T1 - Epigenetic therapy in hematological cancers

AU - Dimopoulos, Konstantinos

AU - Grønbæk, Kirsten

N1 - Special Issue: Personalized Medicine

PY - 2019/5

Y1 - 2019/5

N2 - The increasing depth of knowledge about cancer biology throughout the last decades, has underlined the importance of not only genetic aberrations, but also epigenetic abnormalities in cancer cells. The extensive exploration of the cancer epigenome has provided insights into key pathways involved in tumorigenesis, as well as has allowed the development of novel epigenetic therapies. In this review, we will present the important role of epigenetic alterations in hematological diseases, with special focus on epigenetically-based targeting of hematological malignancies.

AB - The increasing depth of knowledge about cancer biology throughout the last decades, has underlined the importance of not only genetic aberrations, but also epigenetic abnormalities in cancer cells. The extensive exploration of the cancer epigenome has provided insights into key pathways involved in tumorigenesis, as well as has allowed the development of novel epigenetic therapies. In this review, we will present the important role of epigenetic alterations in hematological diseases, with special focus on epigenetically-based targeting of hematological malignancies.

KW - DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors

KW - DNA Methylation

KW - Epigenesis, Genetic

KW - Hematologic Neoplasms/drug therapy

KW - Histone Deacetylase Inhibitors/therapeutic use

KW - Histones/metabolism

KW - Humans

U2 - 10.1111/apm.12906

DO - 10.1111/apm.12906

M3 - Review

C2 - 30859683

SN - 0903-465X

VL - 127

SP - 316

EP - 328

JO - APMIS. Supplementum

JF - APMIS. Supplementum

IS - 5

ER -